List view / Grid view
PARP inhibitor olaparib has been recommended in NICE’s final draft…
PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer.
Final draft guidance published by the National Institute for Health…
Final draft guidance published by the National Institute for Health and Care Excellence (NICE) has recommended immunotherapy pembrolizumab drug for advanced cervical cancer.
NICE's final draft guidance has recommended the first and only…
NICE's final draft guidance has recommended the first and only gene therapy for children with aromatic L-amino acid decarboxylase (AADC) deficiency.
Nivolumab together with chemotherapy has been recommended in NICE final…
Nivolumab together with chemotherapy has been recommended in NICE final draft guidance for treatment of gastroesophageal cancer.
New therapy Mobocertinib, recommended by NICE, helps slow growth of…
New therapy Mobocertinib, recommended by NICE, helps slow growth of EGFR-positive non-small-cell lung cancer in platinum-based chemo-treated patients.
Pembrolizumab is positively recommended for triple-negative early breast cancer, according…
Pembrolizumab is positively recommended for triple-negative early breast cancer, according to NICE final draft guidance.
The one-time gene therapy treatment for rare, neurodegenerative disease metachromatic…
The one-time gene therapy treatment for rare, neurodegenerative disease metachromatic leukodystrophy (MLD) is the most expensive drug ever evaluated by NICE.
NICE has launched a public consultation for suggestions on updating…
NICE has launched a public consultation for suggestions on updating how it selects the topics to develop guidance on, to improve medicine evaluations.
